文献速递青光眼角膜与眼表疾病

品牌药物与Medicare Part D:眼科医疗提供者的处方模式如何影响成本

Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
PubMed 文献 · Ophthalmology · 2017-06-16

这项回顾性横断面研究分析了2013年Medicare Part D中眼科医疗提供者处方眼科药物的成本,发现眼科提供者品牌药按量和按费用的占比均显著高于其他所有提供者(38% vs 23%,P < 0.001;

要点

  • 眼科提供者品牌药按量占比38%、按费用占比79%,均显著高于其他所有提供者(23%、56%),P < 0.001。

核心结论

  • 眼科医疗提供者按量处方的品牌药物多于任何其他提供者组。
  • 减少眼科提供者处方支出的努力应侧重于增加仿制药的使用,主要通过治疗性替换。
  • 使Medicare能够谈判处方药价格的政策变化可能降低Medicare的成本。

研究设计与样本

  • 回顾性横断面研究,使用2013年Medicare Part D处方者公共使用文件和汇总文件。
  • 研究对象为2013年通过Medicare Part D处方药物的眼科医疗提供者。

主要发现

  • 眼科提供者品牌药按月供应量占比38% vs 其他所有提供者23%(P < 0.001),按总费用占比79% vs 56%(P < 0.001)。

关键数值与推荐

  • 眼科提供者品牌药按量占比38% vs 其他所有提供者23%,P < 0.001。
  • 眼科提供者品牌药按总费用占比79% vs 其他所有提供者56%,P < 0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To quantify costs of eye care providers' Medicare Part D prescribing patterns for ophthalmic medications and to estimate the potential savings of generic or therapeutic drug substitutions and price negotiation. DESIGN: Retrospective cross-sectional study. PARTICIPANTS: Eye care providers prescribing medications through Medicare Part D in 2013. METHODS: Medicare Part D 2013 prescriber public use file and summary file were used to calculate medication costs by physician specialty and drug. Savings from generic or therapeutic drug substitutions were estimated for brand drugs. The potential savings from price negotiation was estimated using drug prices negotiated by the United States Veterans Administration (USVA). MAIN OUTCOME MEASURES: Total cost of brand and generic medications prescribed by eye care providers. RESULTS: Eye care providers accounted for $2.4 billion in total Medicare part D prescription drug costs and generated the highest percentage of brand name medication claims compared with all other providers. Brand medications accounted for a significantly higher proportion of monthly supplies by volume, and therefore, also by total cost for eye care providers compared with all other providers (38% vs. 23% by volume, P < 0.001; 79% vs. 56% by total cost, P < 0.001). The total cost attributable to eye care providers is driven by glaucoma medications, accounting for $1.2 billion (54% of total cost; 72% of total volume). The second costliest category, dry eye medications, was attributable mostly to a single medication, cyclosporine ophthalmic emulsion (Restasis, Allergan, Irvine, CA), which has no generic alternative, accounting for $371 million (17% of total cost; 4% of total volume). If generic medications were substituted for brand medications when available, $148 million would be saved (7% savings); if generic and therapeutic substitutions were made, $882 million would be saved (42% savings). If Medicare negotiated the prices for ophthalmic medications at USVA rates, $1.09 billion would be saved (53% savings). CONCLUSIONS: Eye care providers prescribe more brand medications by volume than any other provider group. Efforts to reduce prescription expenditures by eye care providers should focus on increasing the use of generic medications, primarily through therapeutic substitutions. Policy changes enabling Medicare to negotiate prescription drug prices could decrease costs to Medicare.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Newman-Casey PA, Woodward MA, Niziol LM, et al. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. Ophthalmology. 2017. PMID: 28625684. doi:10.1016/j.ophtha.2017.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。